Onset of IVIG Action in Myositis

Clinical Response and Treatment

The American College of Physicians recommends that IVIG typically begins to show clinical improvement within 12 weeks in myositis patients, with biochemical responses often occurring earlier, before the fourth infusion (approximately 8-12 weeks) 1, 2
Muscle strength improvement, rash resolution, and activities of daily living (ADL) enhancement typically manifest by 12 weeks in dermatomyositis patients 1, 2
The pivotal placebo-controlled trial in 15 DM patients demonstrated improvement after 3 months of monthly IVIG therapy 1, 2
Repeated muscle biopsies in responders showed histologic improvement corresponding to clinical gains 1, 2

In severe myositis with dysphagia, respiratory compromise, or rhabdomyolysis, IVIG has a slower onset of action compared to plasmapheresis 3
Plasmapheresis should be considered for acute or severe disease due to faster action, while IVIG is noted to have slower onset 3
Plasmapheresis immediately after IVIG will remove the immunoglobulin, so timing matters 3

Administer IVIG at 1-2 g/kg monthly (typically divided over 2 consecutive days at 1 g/kg each day) 1, 2
For doses exceeding 80g, extend administration to 3-5 days at 0.4 g/kg to minimize adverse effects 1, 2
Document changes in muscle strength, rash (if DM), and ADL function 1, 2
If no improvement by 12 weeks, consider alternative or additional immunosuppression 3

Using IVIG as monotherapy in severe acute myositis is inappropriate due to its slower onset 3
Not checking IgA levels pre-treatment can cause severe anaphylaxis, so screening is mandatory before first infusion 1, 2